Cargando…
Long-Term Efficacy of Intensive Zoledronate Therapy and Predictors of Retreatment in Paget’s Disease of Bone
Despite the current debate on the best therapeutic approach, i.e. symptomatic vs intensive strategy, one zoledronate (Zol) infusion is effective in most patients with Paget’s disease of bone (PDB), whereas few need retreatment, whose predictors are not well established. We aimed to evaluate long-ter...
Autores principales: | Barale, Marco, Sigrist, Sarah, Bioletto, Fabio, Maiorino, Federica, Ghigo, Ezio, Mazzetti, Riccardo, Procopio, Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429167/ https://www.ncbi.nlm.nih.gov/pubmed/33876253 http://dx.doi.org/10.1007/s00223-021-00848-x |
Ejemplares similares
-
Bone safety of dual-release hydrocortisone in patients with autoimmune primary adrenal insufficiency
por: Bioletto, Fabio, et al.
Publicado: (2023) -
Use of zoledronic acid in the treatment of Paget’s disease
por: Seton, Margaret, et al.
Publicado: (2007) -
Intravenous Zoledronate for a Patient with Paget's Disease
por: Kim, Ki-Choul
Publicado: (2014) -
Zoledronate in the prevention of Paget’s (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget’s disease of bone
por: Cronin, Owen, et al.
Publicado: (2019) -
Response to Zoledronic Acid in Patients with Active Paget's Disease of Bone: A Retrospective Study
por: Durgia, Harsh, et al.
Publicado: (2019)